补气利水方联合康柏西普治疗糖尿病性黄斑水肿的疗效

doi:10.19739/j.cnki.issn1001-9510.2021.03.010

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (681 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the treatment of diabetic macular edema by Buqilishui prescription combined with conbercept.Methods Fifty-two cases (64 eyes) of diabetic macular edema patients were randomly divided into the combined treatment group and the control group. The combined treatment group was treated with Buqilishui prescription combined with intravitreal injection of conbercept, while the control group was treated with only intravitreal injection of conbercept. The BCVA and CMT were observed at 1 month, 3 months and 6 months after the initial treatment, and the times of conbercept injections were countedand compared.Results There were no significant differences in BCVA and CMT before the treatment between the two groups (P＞0.05). BCVA and CMT in 2 groups were significantly improved after the treatment compared with those before the treatment, and the difference was statistically significant (P＜0.05). But there were no significant differences in BCVA and CMT after the treatment at the same time points (P＞0.05). There were significant differences in average times of conbercept injections between the two groups (P＜0.05).Conclusion Conbercept in the treatment of DME can effectively improve the visual acuity of patients with DME, and when it is combined with Buqilishui prescription, can reduce times of intravitreal injection of conbercept.

Key words： Buqilishui prescription conbercept diabetic macular edema

Received: 15 September 2020

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Huabin
	LI Xinmeng
	LI Weiguo
	GONG Yuerong
	FANG Binghua

Cite this article:

ZHENG Huabin,LI Xinmeng,LI Weiguo, et al. Treatment of diabetic macular edema by Buqilishui prescription combined with conbercept[J]. 滨州医学院学报, 2021, 44(3): 204-206.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2021.03.010 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2021/V44/I3/204

[1] 马景学.视网膜病[M]//杨培增.眼科学.9版.北京:人民卫生出版社,2018:194-195.
[2] 谭贵临.非诺贝特对糖尿病视网膜病变的防治研究及其临床转化[J].中华实验眼科杂志,2019,37(10): 828-832.
[3] 杨柳,张婧.糖尿病性黄斑水肿治疗方法的选择[J].中华眼科杂志,2017,53(10):724-728.
[4] 李德爽,张靓,秦波.糖尿病性黄斑水肿的药物治疗及进展[J].国际眼科杂志,2019,19(4):592-595.
[5] 胡元春,接传红,吴正正,等.中药治疗糖尿病黄斑水肿临床用药特征探讨[J].北京中医药大学学报,2018,41(5):434-440.
[6] 雷晓琴,李高彪,张雪倩,等.通络驻景丸联合抗VEGF药物和激光治疗糖尿病性黄斑水肿的临床研究[J].中国中医眼科杂志,2018,28(5):306-309.
[7] 中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.
[8] 邵毅.玻璃体内注射技术规范——2018年欧洲视网膜专家学会共识解读[J].眼科新进展,2018,38(12):1101-1104.
[9] 寇豆,郝晓琳,张仲臣.糖尿病黄斑水肿的治疗进展[J].国际眼科杂志,2016,16(5):864-868.
[10] 黎晓新,白玉婧.抗血管内皮生长因子在眼科治疗中的趋势与挑战[J].中华眼科杂志,2016,52(5):321-324.
[11] NGUYEN Q D, BROWN D M, MARCUS D M, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801.
[12] HEIER J S, KOROBELNIK J F, BROWN D M, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11):2376-2385.
[13] LI F, ZHANG L, WANG Y, et al. One-year outcome of conbercept therapy for diabeticmacular edema[J]. Curr Eye Res, 2018, 43(2):218-223.
[14] PENG Y, ZHANG X, MI L, et al. Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy[J].BMC Ophthalmol, 2017,17(1):87.
[15] 苑维,金明.糖尿病性视网膜病变的中医治疗进展[J].北京中医药大学学报,2004,27(1):89-92.
[16] 寇馨云,金明.黄斑2号方联合激光对糖尿病黄斑水肿患者的临床观察[J].环球中医药,2016,9(8):999-1002.